Safety studies of post-surgical buprenorphine therapy for mice

Karl A. Traul, Jennell B. Romero, Cory Brayton, Louis DeTolla, Nadine Forbes-McBean, Matthew S. Halquist, H. Thomas Karnes, Rachel Sarabia-Estrada, Michael J. Tomlinson, Betty Mae Tyler, Xiaobu Ye, Patricia Zadnik, Michael Guarnieri

Research output: Contribution to journalArticle

Abstract

The use of appropriate analgesia in laboratory mice may be suboptimal because of concerns about adverse events (AE). Target Animal Safety trials were conducted to determine the safety of an extended-release suspension of buprenorphine. Drug or control suspensions were injected subcutaneously in surgically-treated BALB/c mice anesthetized with ketamine–xylazine to mimic post-operative conditions in which the compound might commonly be administered. Single and repeat five-fold (5×) excesses of the 3.25 mg/kg intended dose were used to provoke potential AE. Trials included prospective measurements of weight changes, blood chemistry, hematology, and histopathology. Clinical and histopathology findings were similar in drug-treated and control mice in a four-day trial using a single 16.25 mg/kg, 5× overdose of the drug. In a 12-day trial, which used a total buprenorphine dose of 48.75 mg/kg, clinical and histopathology values were also similar in control and drug-treated female mice. In the male arm of the repeat-overdose trial, two of eight mice died on the morning of day 12, three days following the third 16.25 mg/kg overdose administration. Histopathology did not reveal a cause of death. In a 14-month trial using a single 3.25 mg/kg dose of the drug, no significant findings identified potential AE. These findings indicate a high tolerance to an extended-release buprenorphine suspension administered post-operatively in mice with appropriate husbandry.

Original languageEnglish (US)
Pages (from-to)100-110
Number of pages11
JournalLaboratory Animals
Volume49
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

buprenorphine
Buprenorphine
Safety
histopathology
overdose
therapeutics
Drug and Narcotic Control
mice
drugs
Suspensions
Therapeutics
dosage
Drug Overdose
blood chemistry
Hematology
hematology
analgesia
Analgesia
Cause of Death
death

Keywords

  • adverse events
  • analgesia
  • buprenorphine
  • extended-release
  • mice

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)
  • Medicine(all)

Cite this

Traul, K. A., Romero, J. B., Brayton, C., DeTolla, L., Forbes-McBean, N., Halquist, M. S., ... Guarnieri, M. (2015). Safety studies of post-surgical buprenorphine therapy for mice. Laboratory Animals, 49(2), 100-110. https://doi.org/10.1177/0023677214554216

Safety studies of post-surgical buprenorphine therapy for mice. / Traul, Karl A.; Romero, Jennell B.; Brayton, Cory; DeTolla, Louis; Forbes-McBean, Nadine; Halquist, Matthew S.; Karnes, H. Thomas; Sarabia-Estrada, Rachel; Tomlinson, Michael J.; Tyler, Betty Mae; Ye, Xiaobu; Zadnik, Patricia; Guarnieri, Michael.

In: Laboratory Animals, Vol. 49, No. 2, 01.04.2015, p. 100-110.

Research output: Contribution to journalArticle

Traul, KA, Romero, JB, Brayton, C, DeTolla, L, Forbes-McBean, N, Halquist, MS, Karnes, HT, Sarabia-Estrada, R, Tomlinson, MJ, Tyler, BM, Ye, X, Zadnik, P & Guarnieri, M 2015, 'Safety studies of post-surgical buprenorphine therapy for mice', Laboratory Animals, vol. 49, no. 2, pp. 100-110. https://doi.org/10.1177/0023677214554216
Traul KA, Romero JB, Brayton C, DeTolla L, Forbes-McBean N, Halquist MS et al. Safety studies of post-surgical buprenorphine therapy for mice. Laboratory Animals. 2015 Apr 1;49(2):100-110. https://doi.org/10.1177/0023677214554216
Traul, Karl A. ; Romero, Jennell B. ; Brayton, Cory ; DeTolla, Louis ; Forbes-McBean, Nadine ; Halquist, Matthew S. ; Karnes, H. Thomas ; Sarabia-Estrada, Rachel ; Tomlinson, Michael J. ; Tyler, Betty Mae ; Ye, Xiaobu ; Zadnik, Patricia ; Guarnieri, Michael. / Safety studies of post-surgical buprenorphine therapy for mice. In: Laboratory Animals. 2015 ; Vol. 49, No. 2. pp. 100-110.
@article{ced53f393d0f4e75871396b6a8487bf6,
title = "Safety studies of post-surgical buprenorphine therapy for mice",
abstract = "The use of appropriate analgesia in laboratory mice may be suboptimal because of concerns about adverse events (AE). Target Animal Safety trials were conducted to determine the safety of an extended-release suspension of buprenorphine. Drug or control suspensions were injected subcutaneously in surgically-treated BALB/c mice anesthetized with ketamine–xylazine to mimic post-operative conditions in which the compound might commonly be administered. Single and repeat five-fold (5×) excesses of the 3.25 mg/kg intended dose were used to provoke potential AE. Trials included prospective measurements of weight changes, blood chemistry, hematology, and histopathology. Clinical and histopathology findings were similar in drug-treated and control mice in a four-day trial using a single 16.25 mg/kg, 5× overdose of the drug. In a 12-day trial, which used a total buprenorphine dose of 48.75 mg/kg, clinical and histopathology values were also similar in control and drug-treated female mice. In the male arm of the repeat-overdose trial, two of eight mice died on the morning of day 12, three days following the third 16.25 mg/kg overdose administration. Histopathology did not reveal a cause of death. In a 14-month trial using a single 3.25 mg/kg dose of the drug, no significant findings identified potential AE. These findings indicate a high tolerance to an extended-release buprenorphine suspension administered post-operatively in mice with appropriate husbandry.",
keywords = "adverse events, analgesia, buprenorphine, extended-release, mice",
author = "Traul, {Karl A.} and Romero, {Jennell B.} and Cory Brayton and Louis DeTolla and Nadine Forbes-McBean and Halquist, {Matthew S.} and Karnes, {H. Thomas} and Rachel Sarabia-Estrada and Tomlinson, {Michael J.} and Tyler, {Betty Mae} and Xiaobu Ye and Patricia Zadnik and Michael Guarnieri",
year = "2015",
month = "4",
day = "1",
doi = "10.1177/0023677214554216",
language = "English (US)",
volume = "49",
pages = "100--110",
journal = "Laboratory Animals",
issn = "0023-6772",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Safety studies of post-surgical buprenorphine therapy for mice

AU - Traul, Karl A.

AU - Romero, Jennell B.

AU - Brayton, Cory

AU - DeTolla, Louis

AU - Forbes-McBean, Nadine

AU - Halquist, Matthew S.

AU - Karnes, H. Thomas

AU - Sarabia-Estrada, Rachel

AU - Tomlinson, Michael J.

AU - Tyler, Betty Mae

AU - Ye, Xiaobu

AU - Zadnik, Patricia

AU - Guarnieri, Michael

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The use of appropriate analgesia in laboratory mice may be suboptimal because of concerns about adverse events (AE). Target Animal Safety trials were conducted to determine the safety of an extended-release suspension of buprenorphine. Drug or control suspensions were injected subcutaneously in surgically-treated BALB/c mice anesthetized with ketamine–xylazine to mimic post-operative conditions in which the compound might commonly be administered. Single and repeat five-fold (5×) excesses of the 3.25 mg/kg intended dose were used to provoke potential AE. Trials included prospective measurements of weight changes, blood chemistry, hematology, and histopathology. Clinical and histopathology findings were similar in drug-treated and control mice in a four-day trial using a single 16.25 mg/kg, 5× overdose of the drug. In a 12-day trial, which used a total buprenorphine dose of 48.75 mg/kg, clinical and histopathology values were also similar in control and drug-treated female mice. In the male arm of the repeat-overdose trial, two of eight mice died on the morning of day 12, three days following the third 16.25 mg/kg overdose administration. Histopathology did not reveal a cause of death. In a 14-month trial using a single 3.25 mg/kg dose of the drug, no significant findings identified potential AE. These findings indicate a high tolerance to an extended-release buprenorphine suspension administered post-operatively in mice with appropriate husbandry.

AB - The use of appropriate analgesia in laboratory mice may be suboptimal because of concerns about adverse events (AE). Target Animal Safety trials were conducted to determine the safety of an extended-release suspension of buprenorphine. Drug or control suspensions were injected subcutaneously in surgically-treated BALB/c mice anesthetized with ketamine–xylazine to mimic post-operative conditions in which the compound might commonly be administered. Single and repeat five-fold (5×) excesses of the 3.25 mg/kg intended dose were used to provoke potential AE. Trials included prospective measurements of weight changes, blood chemistry, hematology, and histopathology. Clinical and histopathology findings were similar in drug-treated and control mice in a four-day trial using a single 16.25 mg/kg, 5× overdose of the drug. In a 12-day trial, which used a total buprenorphine dose of 48.75 mg/kg, clinical and histopathology values were also similar in control and drug-treated female mice. In the male arm of the repeat-overdose trial, two of eight mice died on the morning of day 12, three days following the third 16.25 mg/kg overdose administration. Histopathology did not reveal a cause of death. In a 14-month trial using a single 3.25 mg/kg dose of the drug, no significant findings identified potential AE. These findings indicate a high tolerance to an extended-release buprenorphine suspension administered post-operatively in mice with appropriate husbandry.

KW - adverse events

KW - analgesia

KW - buprenorphine

KW - extended-release

KW - mice

UR - http://www.scopus.com/inward/record.url?scp=84937239423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937239423&partnerID=8YFLogxK

U2 - 10.1177/0023677214554216

DO - 10.1177/0023677214554216

M3 - Article

C2 - 25305141

AN - SCOPUS:84937239423

VL - 49

SP - 100

EP - 110

JO - Laboratory Animals

JF - Laboratory Animals

SN - 0023-6772

IS - 2

ER -